Landos Biopharma, Inc. (LABP) Social Stream
LANDOS BIOPHARMA INC (LABP) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering LANDOS BIOPHARMA INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-20 | 6 | $50 | $15 | $32.833 | $4.391 | 647.73% |
| 2021-11-16 | 6 | $50 | $15 | $30 | $4.391 | 583.22% |
| 2022-01-03 | 4 | $50 | $7 | $28.666 | $4.391 | 552.84% |
| 2022-03-24 | 6 | $50 | $7 | $26.166 | $4.391 | 495.9% |
| 2022-04-12 | 6 | $50 | $1.4 | $21.4 | $4.391 | 387.36% |
| 2022-05-12 | 6 | $50 | $0.8 | $24.16 | $4.391 | 450.22% |
| 2022-05-13 | 6 | $50 | $0.8 | $18.2 | $4.391 | 314.48% |
| 2022-08-12 | 5 | $50 | $0.8 | $17.933 | $4.391 | 308.4% |
| 2022-11-11 | 3 | $2 | $0.2 | $1.1 | $4.391 | -74.95% |
| 2023-02-08 | 3 | $2 | $0.1 | $1.05 | $4.391 | -76.09% |
| 2023-03-24 | 2 | $2 | $0.1 | $1.05 | $4.391 | -76.09% |
| 2023-05-12 | 1 | $10 | $10 | $10 | $4.391 | 127.74% |
| 2023-05-16 | 2 | $10 | $1 | $5.5 | $4.391 | 25.26% |
| 2023-11-09 | 1 | $5 | $5 | $5 | $4.391 | 13.87% |
The Trend in the Analyst Price Target
Over the past 20 months, LABP's average price target has gone down $21.17.
LABP reports an average of 713.13% for its upside potential over the past 39 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-08 | 2 | 2 | 0.1 | 1.05 | 0.385 | 172.73% |
| 2023-05-12 | 2 | 10 | 10.0 | 10.00 | 0.298 | 3255.7% |
| 2023-05-16 | 2 | 10 | 1.0 | 5.50 | 0.290 | 1796.55% |
| 2023-05-16 | 2 | 1 | 0.1 | 0.55 | 2.905 | -81.07% |
| 2023-11-09 | 1 | 5 | 5.0 | 5.00 | 3.830 | 30.55% |
LABP Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 1 | 0 | 0 | 1 |
The Trend in the Broker Recommendations
LABP's average broker recommendation rating improved by 0.5 over the prior 35 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, LANDOS BIOPHARMA INC's variance in analysts' estimates is lower than -1922.51% of them.
- LABP has a higher upside potential (average analyst target price relative to current price) than 1396.02% of all US stocks.
- LANDOS BIOPHARMA INC's number of analysts covering the stock is greater than 469.74% of Healthcare stocks.
- To contextualize these metrics, consider that out of stocks in the small market cap category, LANDOS BIOPHARMA INC's average analyst price target is greater than 884.08% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to LANDOS BIOPHARMA INC are TERN, SNSE, and PHVS.
View All Top Stocks by Price Target
Make investment decisions regarding LABP using the data that counts. Try POWR Ratings for free.